Journal of Clinical Pharmacy and Therapeutics · 2009 · 20 citations · 6 references
MedicinePharmacologyPharmacotherapyDrug MetabolismHepatic PharmacotherapyHepatologyCholestatic Liver InjuryHepatic MetabolismHepatic ToxicityHepatobiliary DiseaseLiver DiseaseLiver Function TestsAspartate Aminotransferase ElevationGamma-glutamyl TransferaseHepatic Enzyme AlterationsLiver Enzyme AbnormalitiesSerum Alanine AminotransferaseSerum Aspartate AminotransferaseSerum Bilirubin TestingTotal Serum Bilirubin
We report a case of acute liver injury probably due to fenofibrate. A 50-year-old female without a history of liver disease developed cholestatic hepatitis during her second week of fenofibrate treatment. Laboratory tests on admission showed serum bilirubin 534.0 mcmol/L (conjugated 444.0), alkaline phosphatase (AP) 8.76, gamma-glutamyl traspeptidase (GGT) 20.92, alanine aminotransferase (ALT) 2.6, aspartate aminotransferase (AST) 3.64 mckat/L. Fenofibrate withdrawal and ursodeoxycholic acid (750 mg daily) administration was rapidly followed by a favourable outcome.
6
Fenofibrate for patients with asymptomatic primary biliary cirrhosis
Kazufumi Dohmen, Toshihiko Mizuta, Makoto Nakamuta et al. · World Journal of Gastroenterology · 2004 · 100 citations · Full text
Fenofibrate-induced acute cholestatic hepatitis.
Chiu-Yung Ho, Tzong-Haur Kuo, Tseng‐Shing Chen et al. · PubMed · 2004 · 24 citations
[Autoimmune hepatitis induced by fibrates].
Nathalie Ganne‐Carrié, A de Leusse, Catherine Guettier et al. · PubMed · 1998 · 18 citations
Life Sciences, Immunology, Pathology +10